Paris-based biotech startup Generare, which develops a platform to unearth, decode, and compound previously unread microbial chemistry, has raised €20 million in a Series A.
- Established in 2021 by Guillaume Vandenesch, Generare develops a platform for discovering and analyzing microbial chemistry that has remained largely unexplored.
- The company focuses on unearthing molecules encoded in microbial DNA, decoding their structures and biological functions, and compounding them into potential therapeutics, including antibiotics and cancer treatments.
- Its system systematically extracts, purifies, identifies, and annotates previously unread molecules under real biological conditions, generating a dataset of high-quality molecular information.
- By accessing the estimated 97% of microbial chemistry that has never been screened, Generare enables the identification of novel compounds at a scale unmatched by existing methods.
Details of the deal
- The investment was co-led by Alven and daphni, with participation from Teampact.ventures, Galion.exe, and VIVES Partners.
- The €20 million funding will enable Generare to expand its platform, accelerate the identification of novel molecules, and collaborate with leading partners to transform how nature’s molecular diversity is explored and applied.
"This funding will allow us to scale our platform 10x by 2027, work with the best-in-class partners in drug discovery, crop protection, and compress what took a century of exploration and discovery into a matter of years," Generare's team commented.
